The discovery of nongenotoxic activators of p53: Building on a cell-based high-throughput screen

Seminars in Cancer Biology

Volumn 20, Issue 1, 2010, Pages 40-45

  McCarthy, Anna R ^a   Hollick, Jonathan J ^a   Westwood, Nicholas J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Anti cancer therapies; Cell based high throughput screening; Hit prioritisation; P53 activators; Sirtuins; Tubulin modulators

Indexed keywords

ANTINEOPLASTIC AGENT; CAMBINOL; COMPOUND 9AA; DEHYDROALTENUSIN; DOXORUBICIN; JJ 78; KCG 165; NUTLIN 3; PRIMA 1 COMPOUND; PROTEIN P53; PROTEIN P53 ACTIVATOR; RETRA COMPOUND; RITA COMPOUND; TENOVIN 1; TENOVIN 6; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; DNA DAMAGE; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; MUTANT; NONHUMAN; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952544622     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.02.007     Document Type: Review

References (25)

1. Peterson J.R., Mitchison T.J. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. Chem Biol 2002, 9:1275-1285.
2. Schreiber S.L. The small-molecule approach to biology. Chem Eng News 2003, 81:51-61.
3. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
4. Ishi K., Sugawara F. A facile method to screen inhibitors of protein-protein interactions including MDM2-p53 displayed on T7 phage. Biochem Pharmacol 2008, 75:1743-1750.
5. Vassilev L.T. p53 Activation by small molecules: application in oncology. J Med Chem 2005, 48:4491-4498.
6. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13:23-31.
7. Dey A., Verma C.S., Lane D.P. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008, 98:4-8.
8. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
9. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006, 2:474-479.
10. Bykov V.J.N., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low molecular weight compound. Nat Med 2002, 8:282-288.
11. Wang W., Kim S.H., El-Deiry W.S. Small molecule modulators of p53 family signalling and antitumour effects in p53-deficient human colon tumour xenografts. Proc Natl Acad Sci USA 2006, 103:11003-11008.
12. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., Agapova L.S., Kochetkov D.V., Strom E., et al. Small molecule RETRA suppresses mutant p53-bearing cancer cells through a p53-dependent salvage pathway. Proc Natl Acad Sci USA 2008, 105:6302-6307.
13. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., et al. Small molecule RITA binds to p53, blocks p53-MDM2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-1328.
14. Berkson R.G., Hollick J.J., Westwood N.J., Woods J.A., Lane D.P., Lain S. Pilot screening programme for small molecule activators of p53. Int J Cancer 2005, 115:701-710.
15. Gurova K.V., Hill J.E., Guo C., Prokvolit A., Burdeyla L.G., Samoylova E., et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005, 102:17448-17453.
16. Park S.E., Min Y.K., Ha J.D., Kim B.T., Lee W.G. Novel small molecule induces p53 dependent apoptosis in human colon cancer cells. Biochem Biophys Res Commun 2007, 358:842-847.
17. Kochetkov D.V., Ilyinskaya G.V., Komarov P.G., Strom E., Agapova L.S., Ivanov A.V., et al. Transcriptional inhibition of the human papilloma virus reactivates tumour suppressor p53 in cervical cancer cells. Mol Biol 2007, 41:459-466.
18. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008, 13:454-463.
19. Staples O.D., Hollick J.J., Campbell J., Higgins M., McCarthy A.R., Appleyard V., et al. Characterisation, chemical optimisation and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle 2008, 7:3417-3427.
20. Mooberry S.L., Weiderhold K.N., Dakshanamurthy S., Hamel E., Banner E.J., Kharlamova A., et al. Identification and characterisation of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharm 2007, 72(1):132-140.
21. Giaever G., Shoemaker D.D., Jones T.W., Liang H., Winzeler E.A., Astromoff A., et al. Genomic profiling of drug sensitives via induced halpoinsufficiency. Nat Genet 1999, 21:278-283.
22. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., et al. Antitumor activity of activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Cell 2006, 66:4368-4377.
23. Medda F., Russell R.J.M., Higgins M., McCarthy A.R., Campbell J., Slawin A.Z., et al. Novel cambinol analogues as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem 2009, 52:2673-2682.
24. Dickens M.P., Fitzgerald R., Fischer P.M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Sem Can Biol 2010, 20:10-18.
25. Selivanova G. Therapeutic targeting of p53 by small molecules. Sem Can Biol 2010, 20:46-56.